Catalyst Pharmaceutical Partners, Inc – Nystagmus- congenital motor- autosomal recessive

Submitted By:
[email protected]
Published Date:
January 25, 2020

Access Program Information

<p>The primary objective of the study is:</p>
<p>&bull; To provide patients with <strong>LEMS/CMS/downbeat nystagmus</strong> access to <strong>amifampridine phosphate therapy</strong> where physicians would like to treat with amifampridine phosphate</p>
<p>The secondary objective of the study is:</p>
<p>&bull; To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus</p>

Rare Disease:
Nystagmus- congenital motor- autosomal recessive